Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.70
- Piotroski Score 5.00
- Grade N/A
- Symbol (SCLXW)
- Company Scilex Holding Company
- Price $0.26
- Changes Percentage (-13.33%)
- Change -$0.04
- Day Low $0.26
- Day High $0.26
- Year High $0.26
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-114,331,000
Income Statement
Quarterly
Annual
Latest News of SCLXW
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Scilex Holding Company (NASDAQ:SCLX) Analysts Just Cut Their EPS Forecasts Substantially
Analysts have revised Scilex Holding's forecasts negatively, cutting revenue and EPS estimates. Despite a recent stock price increase, demand impact remains uncertain. Revenue growth is expected to ac...
By Yahoo! Finance | 5 months ago
